CoronaryAtlas logo
CoronaryAtlas
Fibronectin
Pathway / Platelet adhesion & activation

Fibronectin

FN1protein

Fibronectin mediates platelet adhesion to exposed matrix and fibroblast paracrine signaling; dysregulation marks plaque instability and thrombotic coronary events.

Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationalePlatelet adhesion substrate; reduced in STEMI platelet releasate; cell adhesion hub in plaque instability.
Also acts inCap degradation / rupture, Endothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates5
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000115414

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
67
A — assay feasibility
72
E — evidence strength
75
T1DI (composite)
27
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 3/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 19 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.468
Open Targets association (myocardial_infarction)

Literature evidence(12)